AIM: To investigate changes on magnetic resonance imaging (MRI) which occur with intracavitary Gliadel wafer placement in patients with glioblastoma multiforme (GBM). METHODS: This retrospective Health Insurance Portability and Accountability Act-compliant study was approved by the institutional review board, with a waiver of informed consent. A total of eight patients aged 29-67 years with GBM underwent Gliadel wafer placement. T2-weighted/FLAIR images and post-contrast T1-weighted images both before and after wafer placement were retrospectively reviewed in consensus to determine changes in the following parameters: appearance of the pericavitary tissue, pattern of tumor recurrence or progression and appearance of the Gliadel wafer itself. RESULTS: Five out of the eight patients had a progressive increase in enhancement and pericavitary T2/ FLAIR hyperintensity within the first 2 mo and a subsequent decrease in these MRI findings. None of these patients had tumor recurrence within the first 6 mo. Three out of the eight patients demonstrated a progressive increase in enhancement and pericavitary T2 hyperintensity, which continued after the first 6 mo, and were subsequently diagnosed with true tumor progression. There was no increase in distant/nonlocal tumor recurrence. The Gliadel wafer appearance changed over time. CONCLUSION: Pseudoprogression is common after intracavitary Gliadel wafer placement and thus care should be taken before diagnosing tumor progression or recurrence within the first 2 mo.
AIM: To investigate changes on magnetic resonance imaging (MRI) which occur with intracavitary Gliadel wafer placement in patients with glioblastoma multiforme (GBM). METHODS: This retrospective Health Insurance Portability and Accountability Act-compliant study was approved by the institutional review board, with a waiver of informed consent. A total of eight patients aged 29-67 years with GBM underwent Gliadel wafer placement. T2-weighted/FLAIR images and post-contrast T1-weighted images both before and after wafer placement were retrospectively reviewed in consensus to determine changes in the following parameters: appearance of the pericavitary tissue, pattern of tumor recurrence or progression and appearance of the Gliadel wafer itself. RESULTS: Five out of the eight patients had a progressive increase in enhancement and pericavitary T2/ FLAIR hyperintensity within the first 2 mo and a subsequent decrease in these MRI findings. None of these patients had tumor recurrence within the first 6 mo. Three out of the eight patients demonstrated a progressive increase in enhancement and pericavitary T2 hyperintensity, which continued after the first 6 mo, and were subsequently diagnosed with true tumor progression. There was no increase in distant/nonlocal tumor recurrence. The Gliadel wafer appearance changed over time. CONCLUSION: Pseudoprogression is common after intracavitary Gliadel wafer placement and thus care should be taken before diagnosing tumor progression or recurrence within the first 2 mo.
Entities:
Keywords:
Gliadel wafers; Glioblastoma; Glioma; Local chemotherapy; Pseudoprogression
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram Journal: Neuro Oncol Date: 2003-04 Impact factor: 12.300
Authors: S Valtonen; U Timonen; P Toivanen; H Kalimo; L Kivipelto; O Heiskanen; G Unsgaard; T Kuurne Journal: Neurosurgery Date: 1997-07 Impact factor: 4.654
Authors: Dima A Hammoud; Clifford J Belden; Amy C Ho; Gerald J Dal Pan; Edward H Herskovits; Dana C Hilt; Henry Brem; Martin G Pomper Journal: AJR Am J Roentgenol Date: 2003-05 Impact factor: 3.959
Authors: M A Gerosa; M L Rosenblum; G Stevanoni; C Licata; V Della Corte; C Marcon; A Bricolo; G Tridente Journal: Acta Neurol Scand Date: 1986-01 Impact factor: 3.209
Authors: Alf Giese; Thomas Kucinski; Ulrich Knopp; Roland Goldbrunner; Wolfgang Hamel; H M Mehdorn; Jörg C Tonn; Dana Hilt; Manfred Westphal Journal: J Neurooncol Date: 2004-02 Impact factor: 4.130
Authors: Daniela A Bota; Annick Desjardins; Jennifer A Quinn; Mary L Affronti; Henry S Friedman Journal: Ther Clin Risk Manag Date: 2007-10 Impact factor: 2.423
Authors: D Cecchin; I Schiorlin; A Della Puppa; G Lombardi; P Zucchetta; V Bodanza; M P Gardiman; G Rolma; A C Frigo; F Bui Journal: Biomed Res Int Date: 2014-03-27 Impact factor: 3.411